Most recently, a case has been published in which crizotinib, an inhibitor of ALK kinase, induced a partial remission in a patient with an IMT characterized by a RANB2-ALK fusion gene (11). The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.